国金证券：看好管线兑现及前瞻布局AI的药企

Group 1 - The core viewpoint is that the AI-driven pharmaceutical industry is on the verge of breakthroughs, with a focus on companies that have rich pipelines and strong capabilities to deliver results [1] - The first significant milestone will be the approval of the first drug developed by AI, which will attract attention regardless of the superiority of models or data [1] - Companies with self-developed pipelines or collaborative projects entering clinical stages are recommended as key players in this emerging field [1] Group 2 - The AI pharmaceutical sector is characterized as a new cross-disciplinary arena, where potential breakthrough players could be AI-focused pharmaceutical companies, traditional innovative generics with foresight in AI, or new tech companies from non-pharmaceutical sectors [1] - Companies with long-term strategic layouts in the AI field are expected to have high elasticity in achieving relevant results [1]